> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Denali Stock Surges 7%, Adding $213 Million, After Hunter Syndrome Drug Sales Guidance
- URL: https://www.bullished.co/denali-stock-surges-7-adding-213-million-after-hunter-syndrome-drug-sales-guidance-e1c031cc/
- Published: 2026-11-04T14:55:49.000Z
- Updated: 2026-11-04T14:55:49.000Z
- Description: Shares rose after the biotech guided to much higher sales of its Hunter syndrome drug, though a voucher sale drove its profit.
- Author: Matteo Parrino
- Tags: Markets, DNLI, Industry: Healthcare

[Denali Therapeutics](https://www.bullished.co/tag/dnli/) shares climbed 6.84% to $20.78 in Wednesday trading as of 9:54 a.m. ET, adding $213 million in market value, the session after the company said its Hunter syndrome drug AVLAYAH [brought in $17.8 million](https://www.sec.gov/Archives/edgar/data/0001714899/000171489926000107/dnli-20261103.htm?ref=bullished.co) in net product revenue last quarter. Management [expects](https://seekingalpha.com/news/4664392-denali-expects-30m-32m-q4-avlayah-net-product-revenue-as-sanfilippo-bla-filing-remains?ref=bullished.co) AVLAYAH to book $30.0 million to $32.0 million in the fourth quarter.

## A voucher sale props up profit

The quarter's bottom line owes to a different deal. Selling a Priority Review Voucher produced a $194.0 million gain, which left Denali with $70.1 million in net income despite a $126.8 million operating loss, according to its [quarterly report](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000109/dnli-20260930.htm?ref=bullished.co).

The company [held $1.0 billion in cash](https://markets.ft.com/data/announce/detail?dockey=1330-9869427en-6H0LRRQUR7KMRB5KH33FIRQKUN&ref=bullished.co), cash equivalents and marketable securities as of September 30, it said.

## Recovering from a 29% hole

Before the report, Denali's shares sat 29% below their highest close of the past year, set on July 9, as of Tuesday's close. The stock was still up about 18% year to date at that close, against roughly 11% for the S&P 500.

Wednesday's gain put the stock on pace for its biggest one-day rise since June 17, when it rose 7.1%.

## What Denali makes and what's next

Denali's TransportVehicle technology is built to ferry enzymes, oligonucleotides and antibodies into the brain. Its programs target rare lysosomal storage diseases such as Hunter syndrome, and common neurodegenerative diseases such as Alzheimer's and Parkinson's. Its income comes from collaborations with Biogen, Takeda and Sanofi.

The company plans to file a biologics license application, its approval request to the FDA, for its Sanfilippo syndrome program in 2027.

Fourth-quarter AVLAYAH sales will be the first test of the [$30.0 million to $32.0 million guidance](https://markets.ft.com/data/announce/detail?dockey=1330-9869427en-6H0LRRQUR7KMRB5KH33FIRQKUN&ref=bullished.co).

### Sources

- [Denali expects $30M-$32M Q4 AVLAYAH net product revenue as Sanfilippo BLA filing remains planned for 2027 (NASDAQ:DNLI)](https://seekingalpha.com/news/4664392-denali-expects-30m-32m-q4-avlayah-net-product-revenue-as-sanfilippo-bla-filing-remains?ref=bullished.co) — seekingalpha.com
- [Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates](https://finance.yahoo.com/healthcare/articles/denali-therapeutics-inc-dnli-reports-215003286.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Denali Therapeutics GAAP EPS of $0.37 beats by $0.72, revenue of $17.77M misses by $5.13M (DNLI:NASDAQ)](https://seekingalpha.com/news/4664091-denali-therapeutics-gaap-eps-of-0%5F37-beats-by-0%5F72-revenue-of-17%5F77m-misses-by-5%5F13m?ref=bullished.co) — seekingalpha.com
- [Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=1330-9869427en-6H0LRRQUR7KMRB5KH33FIRQKUN&ref=bullished.co) — Financial Times
- [Denali Therapeutics Q3 2026 Earnings Preview | Seeking Alpha](https://seekingalpha.com/news/4662736-denali-therapeutics-q3-2026-earnings-preview?ref=bullished.co) — seekingalpha.com
- [The company's filing (Denali Therapeutics)](https://www.sec.gov/Archives/edgar/data/0001714899/000171489926000107/dnli-20261103.htm?ref=bullished.co) — SEC filing
- [Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates](https://www.zacks.com/stock/news/3022261/denali-therapeutics-inc-dnli-reports-q3-loss-beats-revenue-estimates?cid=CS-ZC-FT-fundamental%5Fanalysis|yseop%5Ftemplate%5F4-3022261&ref=bullished.co) — Zacks Investment Research
- [Denali Therapeutics — Form 10-Q for the quarter ended 2026-09-30 (quarterly results)](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000109/dnli-20260930.htm?ref=bullished.co) — SEC EDGAR

### More on Denali Therapeutics

- [Denali's Cheap Launch Costs Rest On $4.5 Million Of Pre-Approval Inventory Due To Run Out In December](https://www.bullished.co/denalis-cheap-launch-costs-rest-on-4-5-million-of-pre-approval-inventory-due-to-run-out-in-afcec67e/)
- [Denali's Hunter Syndrome Drug Sells $17.8 Million In Quarter, But A $194.0 Million Voucher Sale Made The Profit](https://www.bullished.co/denalis-hunter-syndrome-drug-sells-17-8-million-in-quarter-but-a-194-0-million-voucher-e6519d0e/)

[All Denali Therapeutics (DNLI) coverage →](https://www.bullished.co/tag/dnli/)